Iain Ross has made an immediate mark on ReNeuron, overseeing a restructuring to reduce the British biotech’s head count by 40% within weeks of taking the reins. The cuts extend the stem cell player’s ...

At the most recent follow-up, subjects in the study showed a mean improvement from baseline in visual acuity of + 23 letters in the treated eye. The untreated control eyes did not show meaningful ...

Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi ...

Guildford, UK, 1 February 2008:ReNeuron Group plc (LSE: RENE.L) today provides an update on progress with its Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to ...

LONDON, July 16, 2019 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that it has expanded its intellectual ...

SYDNEY, June 22, 2015 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery ...

Dr David Howard, Senior Postdoctoral Research Associate working on the project using the IZON size exclusion chromatography system for exosome purification. ReNeuron Group Limited, a leading UK ...

Insiders who acquired UK£119k worth of ReNeuron Group plc's (LON:RENE) stock at an average price of UK£0.18 in the past 12 months may be dismayed by the recent 13% price decline. Insiders invest with ...

Biotech firm Reneuron Group has become the latest company to exit from the London Stock Exchange’s AIM as it continues to fight for its life after entering administration. The Welsh company, which was ...

(Reuters) - Biotechnology company ReNeuron Group Plc said its experimental stem cell therapy helped some patients improve motor functions in their arms in a mid-stage study after being disabled by ...

Angel Biotech (LON:ABH), the biopharmaceutical contract manufacturer, has signed a revised, longer-term contract with fellow AIM company Reneuron (LON:RENE) that will see it provide development and ...

of ReNeuron's stem cell derived exosome drug delivery platform, CustomEXTM ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha ...